9
Participants
Start Date
November 30, 2011
Primary Completion Date
December 31, 2012
Study Completion Date
April 30, 2013
HB-110
Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
Seoul St. Mary's Hospital, Seoul
Lead Sponsor
Genexine, Inc.
INDUSTRY